Gottlieb resignation stirs overnight debate

摘要

The surprising resignation of FDA Commissioner Scott Gottlieb, announced on Wednesday afternoon, sent Shockwaves across the healthcare sector, most acutely for early-stage drug developers. Left to speculate on a potential replacement and what the possible consequences might be for drug development, investors' knee-jerk response was "sell now, reassess later".